摘要
目的：对甘露聚糖肽与地榆升白片在恶性肿瘤放射治疗（放疗）中改善白细胞减少症的临床价值评价。方法：共纳入142例患者,随机分为两组：甘露聚糖肽组70例,口服胶囊2粒/次,3次/d;地榆升白片组72例,3片/次,3次/日。放射治疗方案：采用6MV-X线直线加速器外照射患者,均采用常规分割式外照射,即1周5天,1天1次,一次DT1.8~2Gy,总量为DT44~70Gy（6到7周）。应用前瞻性、开放性和平行对照方法,观察两者外周血白细胞水平变化及安全性指标。结果：甘露聚糖肽组与地榆升白片组在显效率（47.46%vs 31.67%,P=0.035）方面,提升白细胞水平效果方面[（7.0±0.8）vs（5.4±0.9）,P=0.005],白细胞数目的最低值[（3.6±0.5）vs（3.2±0.4）,P=0.04]以及两组患者人均集落刺激因子量[（0.59±1.13）vs（2.06±3.75）,P=0.004）具有统计学意义。随访2年,两组患者生活质量的评分以及不良反应的情况中,甘露聚糖肽组均好于地榆升白片组。结论：甘露聚糖肽和地榆升白片两组药物均能显著升高白细胞水平,然而甘露聚糖肽的临床价值更好。
Objective：To evaluate the Clinical value of mannan peptide and Diyu-Shengbai tablet on radiothernpy induced leukopenia.Methods：A prospective parallel randomized controlled clinical study was conducted to compare the clinical value evaluation of one hundred and forty-two cases with malignancy were randomly divided into two groups,mannan peptide group（70 patients）,the average daily dose is 2 capsules 3 times daily and radiothernpy;and Diyu-Shengbai tablet group（72 patients）,the average daily dose is 3 tablets 3 times daily and radiothernpy.Radiation therapy program：6MV-X line linear accelerator patients with external beam radiation.DT1.8~2Gy a day,five days a week,the total is DT44~70Gy.Comparison was made on the efficacy and safety of leukocytes between mannan peptide group and Diyu-Shengbai tablet group.Results：The Significant efficiency between mannan peptide group and Diyu-Shengbai tablet group（47.46% vs 31.67%,P=0.035） the number of WBC in first week [（7.0±0.8） vs（5.4±0.9）,P=0.005],the minimum number of WBC [（3.6±0.5） vs（3.2±0.4）,P=0.04],and the means of used dose of rhG-CSF [（0.62±1.43） vs（2.17±4.05）,P=0.005]with a statistics difference after followup.There are fewer adverse reactions cases and they are not serious in mannan peptide group.Conclusion：Mannan peptide and DiyuShengbai tablet both can significantly elevated white blood cell levels on radiothernpy induced leukopenia,however,mannan peptide is better than Diyu-Shengbai tablet in this study.
出处
《中国医药导刊》
2013年第8期1439-1441,共3页
Chinese Journal of Medicinal Guide
